80 related articles for article (PubMed ID: 7653231)
21. [Use of polymerase chain reaction (PCR) in oncohematology. Detection of minimal residual disease].
Kotliar N; Koziner B
Medicina (B Aires); 1995; 55(2):159-66. PubMed ID: 7565055
[TBL] [Abstract][Full Text] [Related]
22. Monitoring of minimal residual disease in leukemia, advantages and pitfalls.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Ann Med; 2006; 38(7):512-21. PubMed ID: 17101542
[TBL] [Abstract][Full Text] [Related]
23. [Role of molecular genetic investigations in the diagnosis of acute leukemias and in the detection of minimal residual disease].
Földi J; Páldi HP; Nahajevszky S; Jakab K; Regéczi N; Pálóczi K
Orv Hetil; 2001 May; 142(21):1097-102. PubMed ID: 11449838
[TBL] [Abstract][Full Text] [Related]
24. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
Amabile M; Giannini B; Testoni N; Montefusco V; Rosti G; Zardini C; Terragna C; Buonamici S; Ottaviani E; Soverini S; Fiacchini M; Bassi S; de Vivo A; Trabacchi E; Saglio G; Pane F; Baccarani M; Tura S; Martinelli G
Haematologica; 2001 Mar; 86(3):252-9. PubMed ID: 11255271
[TBL] [Abstract][Full Text] [Related]
25. Long-template DNA polymerase chain reaction for the detection of the bcr/abl translocation in patients with chronic myelogenous leukemia.
Waller CF; Dennebaum G; Feldmann C; Lange W
Clin Cancer Res; 1999 Dec; 5(12):4146-51. PubMed ID: 10632353
[TBL] [Abstract][Full Text] [Related]
26. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
[TBL] [Abstract][Full Text] [Related]
27. The use of PCR technology for detecting minimal residual disease in patients with leukemia.
Radich JP
Rev Immunogenet; 1999; 1(2):265-78. PubMed ID: 11253952
[TBL] [Abstract][Full Text] [Related]
28. [The detection of minimal residual disease in leukemia by in vitro DNA amplification].
Yokota S; Seriu T; Misawa S
Rinsho Byori; 1991 Dec; 39(12):1298-307. PubMed ID: 1779467
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease in leukaemia.
Kumar L
Natl Med J India; 1995; 8(4):150-3. PubMed ID: 7633307
[No Abstract] [Full Text] [Related]
30. Comparison of two reverse transcription-polymerase chain reaction methods for detection of AML1/ETO rearrangement in the M2 subtype of acute myeloid leukaemia.
Barragán E; Bonanad S; López JA; Bolufer P; Sanz MA
Clin Chem Lab Med; 1998 Mar; 36(3):137-42. PubMed ID: 9589800
[TBL] [Abstract][Full Text] [Related]
31. Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia.
Biondi A; Rambaldi A
Stem Cells; 1994 Jul; 12(4):394-401. PubMed ID: 7951006
[TBL] [Abstract][Full Text] [Related]
32. Detection and quantitation of genetically marked acute myeloid leukemia by competitive polymerase chain reaction after autologous bone marrow transplantation: a preclinical model for minimal residual disease.
Kühr T; Bechter O; Geley S; Eisterer W; Lukas P; Url M; Dietrich H; Hilbe W; Kofler R; Thaler J
Exp Hematol; 1999 Feb; 27(2):266-71. PubMed ID: 10029166
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
Ghannam J; Dillon LW; Hourigan CS
Br J Haematol; 2020 Jan; 188(1):77-85. PubMed ID: 31804716
[TBL] [Abstract][Full Text] [Related]
34. Detection and significance of minimal residual disease in patients with leukaemia and lymphoma.
Goldman JM; Hughes T
Bone Marrow Transplant; 1991; 7 Suppl 1():66-9. PubMed ID: 2043891
[No Abstract] [Full Text] [Related]
35. Measurement of minimal residual disease in acute leukemia.
Morley A
Leukemia; 1996 May; 10(5):920-2. PubMed ID: 8656691
[No Abstract] [Full Text] [Related]
36. NCCN task force report: molecular markers in leukemias and lymphomas.
Radich JP; Zelenetz AD; Chan WC; Croce CM; Czuczman MS; Erba HP; Horning SJ; Houldsworth J; Smith BD; Snyder DS; Sundar HM; Wetzler M; Winter JN
J Natl Compr Canc Netw; 2009 Jul; 7 Suppl 4():S1-34, quiz S35-6. PubMed ID: 19635230
[TBL] [Abstract][Full Text] [Related]
37. The use of the polymerase chain reaction for the detection of minimal residual malignant disease.
Negrin RS; Blume KG
Blood; 1991 Jul; 78(2):255-8. PubMed ID: 2070062
[No Abstract] [Full Text] [Related]
38. Use of the polymerase chain reaction to detect hypermethylation in the calcitonin gene. A new, sensitive approach to monitor tumor cells in acute myelogenous leukemia.
Fukuhara T; Hooper WC; Baylin SB; Benson J; Pruckler J; Olson AC; Evatt BL; Vogler WR
Leuk Res; 1992 Oct; 16(10):1031-40. PubMed ID: 1405705
[TBL] [Abstract][Full Text] [Related]
39. Detection of minimal residual disease in hematopoietic tissues.
Sharp JG; Bishop M; Chan WC; Greiner T; Joshi SS; Kessinger A; Reed E; Sanger W; Tarantolo S; Traystman M
Ann N Y Acad Sci; 1995 Dec; 770():242-61. PubMed ID: 8597365
[No Abstract] [Full Text] [Related]
40. [Minimal residual disease in acute leukemias--clinical significance].
Deptała A; Kuratowska Z
Pol Arch Med Wewn; 1997 Mar; 97(3):268-74. PubMed ID: 9333773
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
